Allegro Ophthalmics LLC Announces Commencement of First Human Subject Study With ALG-1001 to Treat Vitreomacular Traction
11/4/2013 10:56:05 AM
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced the commencement of a Phase II study of ALG-1001 in patients with vitreomacular traction (VMT).
Help employers find you! Check out all the jobs and post your resume.
comments powered by